静脉铁剂治疗妊娠期非贫血性缺铁的多中心随机对照试验
在巴基斯坦拉合尔三家教学医院开展的多中心、两臂随机试验,纳入600例妊娠期非贫血性缺铁(血红蛋白11-13 g/dL且铁蛋白<30 μg/L)孕妇,比较静脉铁剂1000 mg联合常规口服铁剂与单纯口服铁剂30 mg/d的疗效。
要点
- 静脉铁剂联合口服铁剂较单纯口服铁剂显著提高非贫血性缺铁孕妇分娩前血红蛋白。
- 两组均未报告严重或危及生命的不良事件。
- 建议孕早期考虑铁蛋白筛查,阳性者静脉铁剂治疗有效。
核心结论
- 在非贫血性缺铁孕妇中,与口服铁剂预防相比,静脉铁剂治疗显著改善分娩前母体血红蛋白浓度。
研究设计与样本
- 多中心、两臂、随机对照试验,在巴基斯坦拉合尔三家教学医院进行,共筛查1206例,纳入600例孕妇。
- 纳入标准为年龄≥18岁、单胎妊娠、首次产检时血红蛋白11-13 g/dL且铁蛋白<30 μg/L。
- 随机1:1分配至静脉铁剂1000 mg联合常规口服铁剂组(295例)或口服铁剂30 mg/d预防组(305例)。
- 主要终点为基线至孕36周母体血红蛋白浓度平均变化,采用意向性分析。
主要发现
- 静脉铁组228例分娩(14例早产),口服铁组234例分娩(21例早产;3例无主要终点数据)。
- 无参与者发生严重或危及生命的不良事件。
关键数值与推荐
- 非贫血性缺铁定义为首次产检血红蛋白11-13 g/dL且铁蛋白<30 μg/L。
- 静脉铁剂方案为1000 mg静脉铁联合常规口服铁剂预防。
- 口服铁剂预防方案为每日30 mg口服铁剂。
临床怎么用
- 对于妊娠期非贫血性缺铁孕妇,可考虑在常规口服铁剂基础上加用静脉铁剂以改善分娩前血红蛋白。
- 建议孕早期进行铁蛋白筛查,对非贫血性缺铁阳性者静脉铁剂治疗有效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In non-anaemic iron deficiency during pregnancy, it remains unclear whether the administration of intravenous iron improves maternal and infant outcomes, compared with prophylactic oral iron that is currently recommended for antenatal care. This study evaluated whether the addition of intravenous iron to routine oral prophylaxis had an effect on maternal haemoglobin concentration before delivery in non-anaemic iron deficient pregnant women. METHODS: In this multicentre, two-arm, randomised trial done at three teaching hospitals in Lahore, Pakistan, pregnant women aged 18 years or older with a singleton pregnancy were screened at the first antenatal care booking visit for non-anaemic iron deficiency (haemoglobin 11-13 g/dL at booking with ferritin <30 μg/L). Women with high haemoglobin concentrations were excluded. Participants were randomly assigned (1:1) to an intervention during the second trimester using serially numbered, opaque, identical boxes, prepared by a third party using computer-generated random numbers with variable block sizes. Participants were assigned to either receive 1000 mg of intravenous iron in addition to routine oral iron prophylaxis, or to receive prophylactic 30 mg oral iron daily as the standard of routine care throughout pregnancy. Outcome assessors were masked to group allocation. Participants were followed up to delivery. The primary outcome was the mean change in maternal haemoglobin concentration from baseline to 36 weeks' gestation. We performed the primary analysis applying the intention-to-treat principle in all randomly assigned participants who had data for the primary outcome available (full analysis set). We assessed participants for serious or life-threatening adverse events such as death, cardiac arrest, myocardial infarction, anaphylactic shock, and reactions leading to intensive care admission and discontinuation of treatment. The trial is registered at ClinicalTrials.gov number, NCT04228627, and is completed. FINDINGS: Between Jan 14, 2020, to Aug 29, 2023, 1206 women were screened for eligibility, 606 were ineligible for participation due to reasons including age, gestational age, and haemoglobin concentration, and 600 were enrolled in the study. 295 women were assigned to the intravenous iron group and 305 were assigned to the oral iron prophylaxis group, and all were followed up until delivery. 228 women delivered in the intravenous iron group (14 preterm), and 234 women delivered in the oral iron prophylaxis group (21 preterm; three without primary outcome data). Maternal haemoglobin concentration before delivery was 11·6 g/dL (SD 0·5) in the intravenous iron group and 10·8 g/dL (0·7) in the prophylactic oral iron group (mean difference, 0·74 g/dL [95% CI 0·64-0·85]; p<0·0001). None of the participants experienced serious or life-threatening adverse events. INTERPRETATION: Among non-anaemic iron deficient pregnant women, intravenous iron therapy significantly improved maternal haemoglobin before delivery, compared with oral iron prophylaxis. Ferritin screening should be considered in early pregnancy, as intravenous iron therapy is effective in those tested positive for non-anaemic deficiency. FUNDING: None.
引用
- Wasim T, Bushra N, Nasrin T, et al. Intravenous iron for non-anaemic iron deficiency in pregnancy: a multicentre, two-arm, randomised controlled trial. Lancet Haematol. 2026. PMID: 41482443. doi:10.1016/S2352-3026(25)00315-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。